Endothelin Receptor
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB07041 | Zibotentan | 186497-07-4 | Zibotentan is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). |
| FB20274 | ZD-1611 | 186497-38-1 | ZD1611 is an endothelin receptor antagonist. |
| FB09610 | Sulfisoxazole | 127-69-5 | Sulfisoxazole is an antagonist of endothelin receptor that can be used as a sulfonamide antibacterial agent. |
| FB01790 | Sodium Ferulate | 24276-84-4 | Sodium ferulate is the sodium salt of ferulic acid which is used for the treatment of cardiovascular disease. |
| FB00399 | Sitaxsentan Sodium | 210421-74-2 | Sitaxsentan sodium has selectory antagonism of endothelin A (ETA) receptor with the IC50 and Ki value of 1.4 nM and 0.43 nM respectively. |
| FB00400 | Sitaxsentan | 184036-34-8 | Sitaxsentan is a selective endothelin A (ETA) receptor antagonist. |
| FB03273 | Ro 46-2005 | 150725-87-4 | Ro 46-2005 is an antagonist of endothelin receptor. |
| FB06190 | Macitentan N-Butyl Analogue | 556797-16-1 | Macitentan n-butyl analogue is a n-butyl analogue of Macitentan (ACT064992), which is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). |
| FB06664 | Macitentan | 441798-33-0 | Macitentan is an antagonist of endothelin receptor A (ETA) with IC50 of 0.5 nM. It is developed for treatment of pulmonary arterial hypertension (PAH). |
| FB00157 | J-104132 | 198279-45-7 | J-104132 is a potent, orally active ETA/ETB receptor antagonist, with Kis of 0.034 nM and 0.104 nM for cloned human ETA and ETB receptors expressed in CHO cells. |
| FB17184 | IRL-2500 | 169545-27-1 | IRL-2500 is a potent endothelin receptor antagonist with IC50 values of 1.3 and 94 nM for ETB and ETA receptors respectively. |
| FB11233 | HJP272 | 1072467-37-8 | HJP272, an endothelin receptor antagonist, attenuates lipopolysaccharide-induced acute lung injury. |
| FB17186 | FR 139317 | 142375-60-8 | FR 139317 is selective antagonist of ETA endothelin receptor with Ki values of 1 nM and 7.3 μM for ETA and ETB subtypes respectively. |
| FB12882 | Darusentan | 171714-84-4 | Darusentan is an antagonist of endothelin ETA receptor and it can be used to treat congestive heart failure and hypertension. |
| FB10877 | Clazosentan | 180384-56-9 | Clazosentan is a potent endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury. |
| FB09426 | BQ-788 Sodium | 156161-89-6 | BQ-788 sodium salt is a potent, selective ETB receptor antagonist with IC50 of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM. |
| FB03988 | BQ-788 | 173326-37-9 | BQ-788 is a potent and selective endothelin receptor subtype B (ETB) antagonist with IC50 of 1.2 nM (inhibits 125I-labeled endothelin 1 (ET-1) binding to ETB receptors on human Girardi heart cells). |
| FB02801 | BQ-123 | 136553-81-6 | BQ-123 is a specific antagonist of endothelin A receptor (ETA) and the IC50 is 7.3 nM. |
| FB08662 | Bosentan Hydrate | 157212-55-0 | Bosentan is an endothelin (ET) receptor antagonist of ET-A (Ki = 4.7 nM) and ET-B (Ki = 95 nM). |
| FB10705 | Bosentan | 147536-97-8 | Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively. |
| FB16763 | BMS 182874 Hydrochloride | 1215703-04-0 | BMS 182874 Hydrochloride is a potent and selective and competitive non-peptide endothelin ETA receptor antagonist with Ki of 48 nM. |
| FB07947 | Avosentan | 290815-26-8 | Avosentan is a potent, selective endothelin receptor (ETA receptor) antagonist. |
| FB03993 | Atrasentan | 173937-91-2 | Atrasentan is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
| FB07604 | Atrasentan HCl | 195733-43-8 | Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
| FB08844 | Ambrisentan | 177036-94-1 | Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor (IC50s = 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively). |
| FB02259 | ACT-132577 | 1103522-45-7 | ACT-132577 is the major and pharmacologically active metabolite of macitentan), which is dual ETA/ETB endothelin (ET) receptor antagonist designed for tissue targeting. |
| FB17188 | A 127722 | 195704-72-4 | A 127722 is a potent ETA endothelin receptor antagonist with IC50 values of 0.11 nM and 98 nM for human ETA and ETB receptors, respectively. |